Park National Corp OH Reduces Stock Position in Danaher Co. (NYSE:DHR)

Park National Corp OH decreased its position in Danaher Co. (NYSE:DHR) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,323 shares of the conglomerate’s stock after selling 1,497 shares during the quarter. Park National Corp OH’s holdings in Danaher were worth $19,127,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of DHR. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher during the third quarter valued at approximately $50,000. Darwin Wealth Management LLC bought a new position in shares of Danaher during the third quarter valued at approximately $55,000. Finally, Dunhill Financial LLC lifted its stake in Danaher by 45.1% in the third quarter. Dunhill Financial LLC now owns 222 shares of the conglomerate’s stock worth $62,000 after acquiring an additional 69 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of NYSE DHR opened at $239.00 on Wednesday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm’s 50-day moving average price is $236.17 and its 200-day moving average price is $254.11. Danaher Co. has a 52-week low of $222.53 and a 52-week high of $281.70. The company has a market cap of $172.62 billion, a PE ratio of 45.61, a PEG ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the firm posted $2.02 EPS. The firm’s revenue was up 3.1% on a year-over-year basis. As a group, analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s payout ratio is presently 20.61%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DHR. Royal Bank of Canada reduced their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Raymond James decreased their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. UBS Group cut their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Finally, Robert W. Baird lowered their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.